TG Therapeutics | TGTX - Current Assets


TG Therapeutics reported $1.09B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Alaunos Therapeutics USD 970K 1.02M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Ardelyx USD 381.87M 447K Mar/2026
Arrowhead Research USD 1.84B 665.36M Mar/2026
Bayer EUR 35.3B 2.39B Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
Corcept Therapeutics USD 426.03M 59.43M Mar/2026
Curis USD 6.92M 7.5M Dec/2025
Gilead Sciences USD 18.64B 1.25B Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Novartis USD 26.61B 3.85B Mar/2026
Novavax USD 850.82M 127.46M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
TG Therapeutics USD 1.09B 456.2M Mar/2026
Verastem USD 223.41M 69.36M Dec/2025
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026